C4 Therapeutics, Inc. financial data

Symbol
CCCC on Nasdaq
Location
Watertown, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 554% % -1.7%
Debt-to-equity 66% % 23%
Return On Equity -64% % -52%
Return On Assets -39% % -40%
Operating Margin -431% % -22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96,914,418 shares 37%
Common Stock, Shares, Outstanding 74,174,515 shares 5.1%
Entity Public Float $306,036,742 USD 136%
Common Stock, Value, Issued $7,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 72,563,311 shares 4.2%
Weighted Average Number of Shares Outstanding, Diluted 72,563,311 shares 4.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $30,108,000 USD -11%
Research and Development Expense $111,771,000 USD 3%
General and Administrative Expense $37,390,000 USD -11%
Operating Income (Loss) $129,786,000 USD -8.8%
Nonoperating Income (Expense) $10,836,000 USD -23%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $118,950,000 USD -13%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $119,081,000 USD -13%
Earnings Per Share, Basic -1 USD/shares 1.2%
Earnings Per Share, Diluted -1 USD/shares 1.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $58,809,000 USD -1.4%
Cash, Cash Equivalents, and Short-term Investments $199,800,000 USD -30%
Accounts Receivable, after Allowance for Credit Loss, Current $6,542,000 USD -37%
Assets, Current $206,864,000 USD -24%
Property, Plant and Equipment, Net $5,134,000 USD -17%
Operating Lease, Right-of-Use Asset $41,961,000 USD -29%
Other Assets, Noncurrent $211,000 USD -96%
Assets $265,488,000 USD -29%
Accounts Payable, Current $1,333,000 USD -11%
Contract with Customer, Liability, Current $17,126,000 USD -18%
Liabilities, Current $35,945,000 USD -17%
Contract with Customer, Liability, Noncurrent $19,888,000 USD -31%
Operating Lease, Liability, Noncurrent $55,247,000 USD -10%
Liabilities $111,080,000 USD -17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $87,000 USD -81%
Retained Earnings (Accumulated Deficit) $718,207,000 USD -20%
Stockholders' Equity Attributable to Parent $154,408,000 USD -36%
Liabilities and Equity $265,488,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $33,285,000 USD -84%
Net Cash Provided by (Used in) Financing Activities $46,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $29,125,000 USD
Common Stock, Shares Authorized 300,000,000 shares 100%
Common Stock, Shares, Issued 74,174,515 shares 5.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,206,000 USD 89%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $62,252,000 USD -1.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $173,540,000 USD 19%
Deferred Tax Assets, Gross $191,619,000 USD 16%
Operating Lease, Liability $65,756,000 USD -7.4%
Depreciation $1,601,000 USD 38%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $119,449,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid $80,217,000 USD -9.9%
Property, Plant and Equipment, Gross $15,533,000 USD 3%
Operating Lease, Liability, Current $6,216,000 USD 10%
Lessee, Operating Lease, Liability, to be Paid, Year Two $9,366,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $9,093,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14,461,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three $9,646,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $62,429,000 USD 2.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $11,362,000 USD 18%
Operating Lease, Payments $2,249,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $456,000 USD 1.8%
Share-based Payment Arrangement, Expense $23,327,000 USD -16%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%